Immuneering plans Phase 2 trial of atebimetinib in anaplastic thyroid cancer
IMRX•Immuneering presented preclinical findings supporting a planned Phase 2 trial of atebimetinib with chemotherapy in second-line anaplastic thyroid cancer. In an animal model, the combination controlled tumors better than chemotherapy alone or dabrafenib with trametinib, including after targeted therapy.




